Menopause Brain Fog Isn’t Dementia. But Your Doctor Can’t Tell You That Because They Don’t Know.
The cognitive changes of perimenopause are real, measurable, and for most women, temporary. But a generation of undertrained physicians can’t deliver reassurance because they never learned about it.
She was 47, a litigator, and she was losing words.
Not obscure words. Words she had used in depositions for twenty years. She would stand in front of a judge and reach for a term she had deployed a thousand times and find nothing. A blank. A gap where language used to be.
She went to her primary care physician. He told her she was stressed. She went to her gynecologist. The gynecologist ordered basic labs and said everything looked normal. She asked about menopause. The gynecologist said she was “too young.”
She Googled “memory loss at 47” at 2 a.m. and spent an hour reading about early-onset Alzheimer’s disease. She didn’t sleep that night. Or the next.
Nobody told her that what she was experiencing had a name, a mechanism, and for most women, a resolution. Nobody told her because her doctors didn’t know.
The Fear Nobody Addresses
Here is what happens in exam rooms across the country every day: a woman in her mid-to-late 40s describes difficulty concentrating, word-finding problems, trouble with multitasking she used to handle effortlessly, and a general sense that her brain is not working the way it used to. She is terrified.
She is terrified because women account for nearly two-thirds of Alzheimer’s diagnoses. She is terrified because she watched her mother or grandmother disappear into dementia. She is terrified because every article about “cognitive decline” in midlife reads like a death sentence.
And her doctor, more often than not, does one of three things: orders a basic cognitive screening test that she passes easily, attributes her symptoms to stress or depression, or shrugs and says there is nothing to be done.
What the doctor almost never does is say: “What you’re experiencing is a well-documented phenomenon of the menopause transition. It has been studied in large longitudinal cohorts. For most women, it resolves. Let me explain what’s happening in your brain and what you can do about it.”
The doctor doesn’t say this because the doctor was never taught it.
What the Science Actually Shows
The largest and most rigorous longitudinal data on cognition during the menopause transition comes from the Study of Women’s Health Across the Nation, known as SWAN. This study followed 2,362 women with serial cognitive testing over multiple years and found something important: perimenopause is associated with a transient decrement in processing speed and verbal memory [1].
The word “transient” matters enormously.
The SWAN findings showed that during late perimenopause, women stopped showing the expected improvement on repeated cognitive tests. In middle-aged adults, when you give the same test multiple times, scores normally get better because of practice effects. During perimenopause, that learning stopped. Then, after menopause, the learning curve resumed [1, 2].
This is not the pattern of a degenerative disease. This is the pattern of a system in transition.
The Penn Ovarian Aging Study followed 403 women over 14 years and found a similar picture: difficulties in verbal memory during perimenopause that resolved in postmenopause, though some challenges with verbal learning persisted longer [3]. Dr. Pauline Maki, one of the foremost researchers in this field, published a clinical guide in Climacteric in 2022 summarizing the evidence: cognitive complaints during menopause are real and measurable, they emerge when menstrual cycles become irregular, they commonly normalize after menopause, and they are not an early phase of a dementing disorder [4].
About 60% of women going through the menopause transition report memory problems. But when formally tested, most remain within the normal cognitive range. About 11 to 13% show clinically significant impairment [4]. That means the vast majority of women experiencing brain fog are experiencing a normal, time-limited neurological event, not the beginning of the end.
Your Brain Is Remodeling, Not Declining
In 2021, neuroscientist Lisa Mosconi and her team at Weill Cornell Medicine published a landmark study in Scientific Reports that changed how we understand the menopausal brain. Using PET and MRI brain imaging on 161 women across premenopausal, perimenopausal, and postmenopausal stages (with age-matched male controls), they documented substantial differences in brain structure, connectivity, and energy metabolism across the menopause transition [5].
Here is what they found: during perimenopause, there is a measurable dip in gray matter volume, white matter volume, and glucose metabolism in the brain. The brain’s primary fuel source becomes less efficient. This correlates exactly with the symptoms women describe: the fog, the word-finding difficulty, the sensation that thinking requires more effort than it should.
But here is the part that should be in every physician’s talking points: when the team followed postmenopausal participants, brain biomarkers largely stabilized. Gray matter volume recovered in key regions involved in cognitive aging [5]. The brain compensated for declining estrogen by increasing cerebral blood flow and shifting to alternative energy pathways.
Mosconi described this as a brain in “remodeling,” comparing it to a machine that once ran on gas and is now switching to electricity [6]. The transition period is rough. The destination is functional.
This distinction matters because the narrative women encounter on social media is catastrophic. Viral claims that the menopausal brain “literally eats itself” without hormone therapy are not supported by the evidence. They are marketing dressed as neuroscience. And they drive terrified women toward unregulated products promising to rescue their “degenerating” brains.
The Lancet Just Settled a Major Question
In December 2025, The Lancet Healthy Longevity published the most comprehensive systematic review and meta-analysis to date on hormone therapy and dementia risk. Commissioned by the World Health Organization, it analyzed data from over one million participants across 10 studies [7].
The conclusion: no significant association between menopause hormone therapy and the risk of dementia or mild cognitive impairment. Not protective. Not harmful. Neutral.
Subgroup analyses found no evidence for a “critical window” of timing. Starting hormone therapy between ages 45 and 55 did not reduce dementia risk. Using it for less than five years, between five and ten years, or longer than ten years showed no consistent effect in either direction [7, 8].
This matters for two reasons.
First, it takes dementia fear off the table for women considering hormone therapy for menopausal symptoms. The FDA’s now-removed black box warning had included language about increased dementia risk, which was based on the Women’s Health Initiative Memory Study, a trial that enrolled women at an average age of 65. That finding was never applicable to women starting hormone therapy at menopause, and the Lancet review confirms it: no evidence of increased risk [7].
Second, it reins in the opposite overclaim. Hormone therapy should not be prescribed specifically to prevent dementia. The data don’t support it. The Lancet Commission on Dementia Prevention, the UK’s NICE guidelines, and now this WHO-commissioned review all agree: hormone therapy decisions should be guided by symptom management and individual risk-benefit assessment, not by promises of cognitive protection that the evidence doesn’t substantiate [7, 9].
This is what evidence-based medicine looks like. Not fear. Not false promises. Honest data, honestly communicated.
The Training Gap That Makes All of This Worse
Here is where the story becomes a professional accountability problem.
A 2023 survey of 99 U.S. OB/GYN residency program directors found that only 31.3% reported having a menopause curriculum in their program. Meanwhile, 92.9% of those same program directors agreed that residents nationwide should have access to a standardized menopause curriculum [10]. They know the training is missing. They just haven’t built it.
Only 20% of OB/GYN residencies offer dedicated menopause training [11]. One in five family medicine, internal medicine, and OB/GYN residents reported receiving no menopause lectures during residency. Not inadequate lectures. Zero [12]. And only 6.8% of residents felt adequately prepared to manage women experiencing menopause [12].
A global review published in Best Practice & Research Clinical Obstetrics & Gynaecology concluded that training on menopause management is “profoundly inadequate even nowadays” [13].
Think about this: approximately 1.1 billion women worldwide are menopausal. The physicians responsible for their care are being trained in programs where menopause is, at best, an afterthought. A woman walks in with brain fog at age 48 and her gynecologist, who completed four years of residency focused largely on pregnancy and surgery, may genuinely not know that the SWAN study exists. May not know about neural remodeling. May not know the Lancet data. May not know that the right answer is: “This is normal, it’s temporary for most women, and here’s what we can do.”
Instead, the physician orders a depression screening or a thyroid panel and moves on.
What’s Actually Driving the Fog
The cognitive changes of perimenopause aren’t random. They have identifiable drivers, and some of them are treatable:
Estrogen withdrawal. Estrogen receptors are densely concentrated in the hippocampus and prefrontal cortex, the brain regions responsible for memory and executive function. When estrogen fluctuates wildly and then drops, these regions are directly affected [5, 14]. This is not a vague hormonal theory. It has been visualized on brain scans.
Sleep disruption. Night sweats fragment sleep architecture. Poor sleep directly impairs memory consolidation, attention, and executive function. Many women experiencing “brain fog” are actually experiencing the cognitive consequences of months or years of disrupted sleep [15].
Vasomotor symptoms. Hot flashes are not just uncomfortable. Objectively measured hot flashes (as opposed to self-reported ones) have been associated with worse verbal memory performance [4]. The thermoregulatory disruption itself may affect brain function.
Mood changes. Depression and anxiety, both more common during the menopause transition, independently impair cognitive processing speed and verbal memory [2].
This means that treating the treatable components, managing vasomotor symptoms, addressing sleep disruption, treating depression and anxiety, can meaningfully improve cognitive function. Not because these treatments fix the brain fog directly, but because they remove the factors compounding it.
What You Should Know
If you are in your mid-40s to mid-50s and experiencing cognitive changes, here is what the evidence supports:
Your brain is not degenerating. The cognitive changes of perimenopause are well-documented, time-limited for most women, and reflect a brain in transition, not in decline. The SWAN study, the Penn Ovarian Aging Study, and Mosconi’s neuroimaging work all point in the same direction: this is temporary.
You probably don’t need a dementia workup. Alzheimer’s disease is rare in women under 60. If your cognitive complaints began around the time your periods became irregular, the most likely explanation is the menopause transition, not neurodegeneration. If you are concerned, formal neuropsychological testing can distinguish between perimenopause-associated cognitive changes and early dementia far better than a screening questionnaire.
Hormone therapy may help your symptoms, but not through the brain. The strongest evidence for cognitive improvement with hormone therapy is indirect: by reducing hot flashes and improving sleep, it addresses the factors that are worsening your cognition. Don’t take hormone therapy specifically for “brain protection.” That’s not what the data show.
Lifestyle interventions matter. Aerobic exercise, sleep hygiene, stress management, and social engagement all have evidence supporting their role in cognitive function during the menopause transition. These are not consolation prizes. They are interventions that target the same pathways affected by estrogen withdrawal.
Be skeptical of anyone selling you brain rescue. If a product claims to “treat cognitive decline during menopause” or prevent your brain from “eating itself,” ask for the randomized trial. If there isn’t one, you’re being marketed to, not treated.
The Professional Failure
There is no excuse for the training gap. Menopause is not a rare condition. It is not a niche interest. It is a universal biological event affecting half the population, with well-characterized effects on cognition, bone, cardiovascular health, urogenital function, and mental health. The idea that a physician can complete a four-year OB/GYN residency without a structured menopause curriculum and then take care of women for the next thirty years is not a gap. It is a failure of professional education.
The data are here. The SWAN study has been publishing for over two decades. Maki’s clinical guide for health professionals has been available since 2022. The Lancet review was commissioned by the WHO. This is not emerging science. It is established science that the medical education system has failed to teach.
Every woman going through perimenopause deserves a physician who can look her in the eye and say: “Your brain fog is real. It’s not dementia. Here’s what’s happening and here’s what we can do.” That this remains the exception rather than the rule is a problem we created, and one we can fix.
If this changed how you understand what’s happening to your brain, share it with a friend who needs to hear it. Subscribe to ObGyn Intelligence for evidence-based women’s health without the fear.
References
Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in mid-life women. Neurology. 2009;72(21):1850-1857.
Greendale GA, Wight RG, Huang MH, et al. Menopause-associated symptoms and cognitive performance: results from the Study of Women’s Health Across the Nation. Am J Epidemiol. 2010;171(11):1214-1224.
Epperson CN, Sammel MD, Freeman EW. Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab. 2013;98(9):3829-3838.
Maki PM, Jaff NG. Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570-578.
Mosconi L, Berti V, Dyke J, et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep. 2021;11:10867.
Mosconi L. The Menopause Brain: New Science Empowers Women to Navigate the Pivotal Transition with Knowledge and Confidence. Avery; 2024.
Melville M, He L, Desai R, et al. Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2025;6(12):100803.
University College London. Menopause hormone therapy does not appear to impact dementia risk. UCL News. December 22, 2025.
Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628.
Allen JT, et al. Needs assessment of menopause education in United States obstetrics and gynecology residency training programs. Menopause. 2023;30(10):999-1005.
Cuyuna Regional Medical Center. Addressing the Knowledge Gap: Menopause. January 2025.
The Flow Space. Most medical schools lack menopause training. August 29, 2024.
Armeni E, Paschou SA, Gkika I, et al. Menopause medical education around the world: the way forward to serve women’s health. Best Pract Res Clin Obstet Gynaecol. 2022;81:44-59.
Metcalf CA, Duffy KA. Cognitive problems in perimenopause: a review of recent evidence. Curr Psychiatry Rep. 2023;25(10):501-511.
Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol. 2014;142:90-98.